SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharmaids Pharma - Quaterly Results

28 May 2024 Evaluate
A slight decline in the revenue of Rs. 0.07 millions was seen for the March 2024 quarter as against Rs. 0.00 millions during year-ago period.The Net Loss for the quarter ended March 2024 is Rs. -22.38 millions as compared to Net Loss of Rs. -61.62 millions of corresponding quarter ended March 2023 Operating profit Margin for the quarter ended March 2024 improved to -17.77% as compared to -86.02% of corresponding quarter ended March 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 0.07 0.00 0.00 0.28 0.00 0.00 0.28 0.00 0.00
Other Income 0.31 0.00 0.00 7.95 0.00 0.00 7.95 0.00 0.00
PBIDT -17.77 -86.02 -79.34 -55.76 -98.91 -43.63 -55.76 -98.91 -43.63
Interest 2.87 0.02 14250.00 3.33 0.00 0.00 3.33 0.00 0.00
PBDT -20.64 -86.04 -76.01 -59.09 -98.91 -40.26 -59.09 -98.91 -40.26
Depreciation 0.46 0.01 4500.00 1.77 0.17 941.18 1.77 0.17 941.18
PBT -21.10 -86.05 -75.48 -60.86 -99.08 -38.57 -60.86 -99.08 -38.57
TAX 1.28 -24.43 -105.24 -11.37 -23.52 -51.66 -11.37 -23.52 -51.66
Deferred Tax 1.28 -24.43 -105.24 -11.37 -23.52 -51.66 -11.37 -23.52 -51.66
PAT -22.38 -61.62 -63.68 -49.49 -75.56 -34.50 -49.49 -75.56 -34.50
Equity 352.68 214.44 64.47 352.68 214.44 64.47 352.68 214.44 64.47
PBIDTM(%) -25385.71 0.00 0.00 -19914.29 0.00 0.00 -19914.29 0.00 0.00

Pharmaids Pharma Share Price

30.92 -0.49 (-1.56%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×